The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine
The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron
The Patent Battlefield: How IP Portfolios Reveal the True Winners in the $1.8 Trillion Space Economy
Recent Comments